



(51) International Patent Classification:

A61K 38/17 (2006.01) C07K 14/475 (2006.01)
A61K 39/395 (2006.01) C07K 16/22 (2006.01)
A61K 47/50 (2017.01) G01N 33/53 (2006.01)
A61P 35/00 (2006.01) G01N 33/574 (2006.01)

(21) International Application Number:

PCT/US2019/019786

(22) International Filing Date:

27 February 2019 (27.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/636,825 28 February 2018 (28.02.2018) US

(71) Applicant: **AP BIOSCIENCES, INC.**; 17F, No. 3, Yuan-qu St., Nangang Dist., Taipei City, 115 (TW).

(72) Inventors: **YOU, Jhong-Jhe**; 2F., No. 9, Aly. 61, Ln. 200, Yongji Rd., Xinyi Dist., Taipei City, 110 (TW). **HSU, Ching-Hsuan**; 10F., No. 151, Guangfeng Rd., Bade Dist.,

Taoyuan City, 334 (TW). **HUANG, Po-Lin**; 6F., No. 69, Donghu Rd., Neihu Dist., Taipei City, 114 (TW).

(74) Agent: **MCILVAINE, John, W.** et al.; The Webb Law Firm, One Gateway Center, 420 Ft. Duquesne Blvd., Suite 1200, Pittsburgh, Pennsylvania 15222 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY




Fig. 15A

(57) Abstract: Provided are bispecific proteins that comprise a binding domain binding cell surface protein and a vascular endothelial growth factor (VEGF) inhibiting domain. Provided also is an antibody-drug conjugate that comprises a therapeutic agent and an antibody or an antigen-binding fragment binding PD-L1 and/or a VEGF inhibiting domain, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding fragment by a linker.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*